Shares of AbbVie (ABBV) were lower Friday after posting disappointing third-quarter revenue. The biopharmaceutical company reported revenue of $6.43 billion for the period, which was below analysts' forecasts. Sales of its flagship treatment Humira grew 11.3% to $4.06 billion, which also missed estimates. Earnings of $1.21 a share beat expectations by a penny. For the full-year, AbbVie increased its earnings guidance. It now expects earnings between $4.80 and $4.82, which is higher than its prior outlook. The company also said it will raise its 2017 dividend by 12%.
More from Video
CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.
Breaking down an approach to the long side of this biotech stock.
AMSC CEO discusses that and China challenges.
One of pharma's biggest CEO's talks M&A action on the exchange.